Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1997 1
1999 1
2000 2
2001 1
2002 1
2003 6
2004 4
2005 9
2006 14
2007 16
2008 13
2009 12
2010 16
2011 22
2012 12
2013 23
2014 20
2015 17
2016 18
2017 19
2018 25
2019 19
2020 20
2021 1
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 24235189

268 results
Results by year
Filters applied: . Clear all
Page 1
Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes.
Bosomworth NJ. Bosomworth NJ. Can Fam Physician. 2013 Nov;59(11):1169-80. Can Fam Physician. 2013. PMID: 24235189 Free PMC article. Review.
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW. Nesto RW. Am J Cardiovasc Drugs. 2005;5(6):379-87. doi: 10.2165/00129784-200505060-00005. Am J Cardiovasc Drugs. 2005. PMID: 16259526 Review.
[Diabetic dyslipidaemia and the atherosclerosis].
Márk L, Dani G. Márk L, et al. Orv Hetil. 2016 May 8;157(19):746-52. doi: 10.1556/650.2016.30441. Orv Hetil. 2016. PMID: 27133274 Review. Hungarian.
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
Tenenbaum A, Fisman EZ. Tenenbaum A, et al. Cardiovasc Diabetol. 2012 Oct 11;11:125. doi: 10.1186/1475-2840-11-125. Cardiovasc Diabetol. 2012. PMID: 23057687 Free PMC article. Review.
"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A, Fisman EZ. Tenenbaum A, et al. Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24. Cardiovasc Diabetol. 2010. PMID: 20550659 Free PMC article.
Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z. Reiner Z. Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Nutr Metab Cardiovasc Dis. 2013. PMID: 23932901 Review.
The metabolic basis of atherogenic dyslipidemia.
Vinik AI. Vinik AI. Clin Cornerstone. 2005;7(2-3):27-35. doi: 10.1016/s1098-3597(05)80065-1. Clin Cornerstone. 2005. PMID: 16473258 Review.
Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ, Watson KE, Talbert RL. Cziraky MJ, et al. J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. J Manag Care Pharm. 2008. PMID: 19891279 Review.
Pitavastatin: novel effects on lipid parameters.
Chapman MJ. Chapman MJ. Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Atheroscler Suppl. 2011. PMID: 22152282 Review.
Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating GM. Keating GM. Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Am J Cardiovasc Drugs. 2011. PMID: 21675801 Review.
268 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback